Trial Profile
Biomarkers of Disease and Response to Treatment in Opioid Addiction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Naltrexone (Primary)
- Indications Heroin-related disorders; Opioid-related disorders
- Focus Biomarker; Therapeutic Use
- 11 Feb 2022 Status changed from active, no longer recruiting to completed.
- 08 May 2020 Planned End Date changed from 1 Oct 2020 to 1 Oct 2022.
- 08 May 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2021.